Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely pentazocine hydrochloride 50 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
|
Pentazocine hydrochloride 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
|
Paracetamol 650mg / pentazocine hydrochloride 25mg caplet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
|
Aspirin + pentazocine hydrochloride 325mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely naloxone hydrochloride 500 microgram and pentazocine hydrochloride 50 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
|
Acetaminophen + pentazocine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
|
Product containing naloxone hydrochloride and pentazocine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
|
Aspirin + pentazocine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely naloxone hydrochloride 500 microgram and pentazocine hydrochloride 50 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely pentazocine hydrochloride 50 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely pentazocine hydrochloride 50 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Pentazocine hydrochloride |
Inferred relationship |
Some |
1 |
Pentazocine hydrochloride 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
1 |
Pentazocine hydrochloride 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Pentazocine hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely naloxone hydrochloride 500 microgram and pentazocine hydrochloride 50 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
2 |
Product containing precisely naloxone hydrochloride 500 microgram and pentazocine hydrochloride 50 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Pentazocine hydrochloride |
Inferred relationship |
Some |
2 |
Product containing precisely pentazocine hydrochloride 50 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Pentazocine hydrochloride |
Inferred relationship |
Some |
1 |
Pentazocine hydrochloride 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Pentazocine hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely naloxone hydrochloride 500 microgram and pentazocine hydrochloride 50 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Pentazocine hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely naloxone hydrochloride 500 microgram and pentazocine hydrochloride 50 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Pentazocine hydrochloride |
Inferred relationship |
Some |
2 |